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Abstract
Background: The ability of a bacterial strain to competitively exclude or displace other strains
can be attributed to the production of narrow spectrum antimicrobials, the bacteriocins. In an
attempt to evaluate the importance of bacteriocin production for Escherichia coli strain residence
in the gastrointestinal tract, a murine model experimental evolution study was undertaken.
Results:  Six colicin-producing, yet otherwise isogenic, E. coli strains were administered and
established in the large intestine of streptomycin-treated mice. The strains' persistence, population
density, and doubling time were monitored over a period of 112 days. Early in the experiment only
minor differences in population density between the various colicin-producing and the non-
producing control strains were detected. However, over time, the density of the control strains
plummeted, while that of the colicin-producing strains remained significantly higher (F(7,66) = 2.317;
P < 0.0008).
Conclusion: The data presented here support prior claims that bacteriocin production may play
a significant role in the colonization of E. coli in the gastrointestinal tract. Further, this study suggests
that the ability to produce bacteriocins may prove to be a critical factor in determining the success
of establishing probiotic E. coli in the gastrointestinal tract of humans and animals.
Background
The gastrointestinal (GI) tract of humans is colonized by
Escherichia coli within about 40 hours of birth [1]. This fac-
ultative anaerobe is then stably maintained as a relatively
minor, but critical, component of the large intestine
microflora with a cell density approximately 1000 times
lower than the predominant bacterial genera, such as Bac-
teriodes,  Clostridia, and anaerobic streptococci. E. coli
adheres to, and primarily subsists on, the mucin layer that
coats the epithelial cells of the large intestine. A domi-
nant, resident strain will normally persist in the GI tract
for periods of months to years, until it is eventually
replaced by one of the many transient strains continually
passing through the intestinal lumen. The basis for these
periodic shifts is not known and has recently become the
focus of a large body of research [2].
In part, this increased interest in the dynamics of E. coli
strains is due to dysbiosis, or microbial imbalances of the
normal human microflora of the GI tract. This common
outcome of antibiotic therapies is now considered to be a
contributing factor to many chronic and degenerative dis-
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eases such as irritable bowel syndrome and rheumatoid
arthritis [2]. Attempts to re-establish a healthy microbial
flora, alleviate GI disorders, and control pathogenic E. coli
in humans and animals through the administration of
probiotics, are limited by our ability to choose and prop-
erly administer the most appropriate strains [3,4]. Under-
standing strain dynamics of E. coli in the GI tract may
provide a more sound approach to both probiotic strain
choice and methods of administration [5-8].
One powerful predictor of the ability of a strain of E. coli
to competitively exclude or displace other strains is the
production of one or more of a large family of narrow
spectrum antimicrobials, the bacteriocins. Theoretical
studies have shown that bacteriocin production enhances
the invasion and establishment success of the producing
strains [9,10]. In vivo studies further demonstrate that bac-
teriocin production improves the establishment success of
its producing strain [11]. Similar results were obtained
when mice harboring bacteriocin-sensitive strains were
co-caged with mice harboring bacteriocin-producing
strains. Within a relatively short period (three to five
weeks) the sensitive strains had been displaced by the bac-
teriocin-producing strains [12].
E. coli are prolific producers of their own species-specific
bacteriocins, known as colicins, which were first identi-
fied over 80 years ago [13], and given the name colicin to
identify the producing species. The frequency of colicin
production varies among E. coli populations depending
on the host species diet [14], the relatedness of the E. coli
strains present [15], and the habitat quality [16]. How-
ever, on average, forty percent of the strains in any popu-
lation are likely to produce one or more colicins [17,18].
Over thirty colicins have been characterized to date, all of
which are plasmid-encoded, high molecular weight pro-
teins that are induced in times of stress [19]. Upon release
of colicins from the producing cell, the toxins kill their tar-
gets primarily by membrane permeabilization or nucleic
acid degradation [20]. Genes encoding colicin functions
are found in clusters that include a toxin-encoding gene;
an immunity gene, encoding a protein conferring self-spe-
cific protection to the cell against its own colicin; and, fre-
quently, a lysis gene, encoding a protein involved in
colicin release via lysis or pseudo-lysis of the producing
cell [19].
It has recently been suggested that bacteriocin production
is a critical factor in determining the establishment suc-
cess of probiotic bacteria in humans and animals [21]. To
investigate this hypothesis, we introduced E. coli strains
differing only in the carriage and identity of bacteriocin-
encoding plasmids into the GI tract of mice. The impor-
tance of bacteriocin production in colonization and per-
sistence of their E. coli hosts in the mouse intestine was
elucidated over time providing a rare and novel glimpse
into the impact of bacteriocins on the establishment of
enteric bacteria in the mouse GI tract.
Results
This study was designed to examine the colonization and
persistence of colicinogenic E. coli strains in the mouse GI
tract following a single administration. To this end, six
isogenic strains of E. coli BZB1011 were created differing
in only two characters: (i) the ability to produce a colicin
(determined by the presence or absence of a plasmid
encoding a colicin gene cluster); and (ii) the identity of
the colicin produced (one of the following colicins: A, E1,
E2, E7, K, and N). Mice treated with streptomycin to erad-
icate their resident enterobacterial flora were inoculated
with streptomycin resistant bacteriocin producing (or non
producing control) strains that were then monitored for
112 days by weekly sampling of mouse pellets.
The persistence and population density of colicin 
producers in the mouse GI tract
Figure 1 reports the average number of bacterial colony
forming units (CFUs) detected over the course of the
experiment, with each point representing an average taken
over four mice (two cages with two mice per cage) per col-
icin treatment. A separate graph is provided for each of the
seven colicin treatments employed. Subsamples of iso-
lated colonies were used to verify the strain's colicin phe-
notype by examining their ability to (i) grow in the
presence of their own colicin extract; and (ii) produce a
clearing zone in a lawn prepared from a colicin sensitive
strain (data not shown). Four patterns of strain dynamics
emerged: First, one week after each mouse was inoculated,
all of the strains had successfully established in the mouse
GI tract at relatively high densities, with an average of 105-
107 CFUs (g feces)-1. Second, two colicin treatments (A
and E1) showed no difference in the average number of
CFUs measured over the course of the experiment, with an
average of 7.5 × 105 and 1.4 × 106 CFUs (g feces)-1, respec-
tively. Third, four of the colicin treatments (E2, E7, K and
N) showed a steady, slow decline in density over the
course of the experiment, with average initial and final
densities of 2.4 × 106 and 2.6 × 104 CFUs (g feces)-1,
respectively. Fourth, relative to all other treatments, the
non-colicin producing control strain declined most rap-
idly and was undetectable in samples from day 112 (< 102
CFU (g feces)-1).
A statistically significant difference in strain persistence
was observed over the course of the experiment (time ×
strain, Repeated Measure Analysis, F(7,66) = 2.317, P <
0.0008). A second repeated-measure ANOVA, which
excluded the colicin-free control strain, revealed signifi-
cant difference in persistence times among the colicinBMC Microbiology 2009, 9:165 http://www.biomedcentral.com/1471-2180/9/165
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Colonization of the mouse intestine by colicin producing E. coli strains Figure 1
Colonization of the mouse intestine by colicin producing E. coli strains. Each point represents the mean CFU (g 
feces)-1 determined for two mice in each of two cages. Bars represent the standard error of the log10 for each point. The 
number of cells measured at day 112 for the colicin free strain falls below the limit of detection determined at 102 CFU (g 
feces)-1.
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strains (time × strain, Repeated Measure ANOVA, F(6,55) =
1.896, P < 0.009). These results indicate that the signifi-
cant differences in strain abundance observed over time is
not solely due to the rapid disappearance of the colicin
free control strain and presumably reflect differences
between the more slowly declining strains (colicins K, N,
E2 and E7) and the highly persistent strains (colicins A
and E1).
One week after the initial strain introduction into the
mouse GI tract, no significant differences in density were
observed between the different colicin-producing strains
(one-way ANOVA at t = 0, F(6,7) = 0.136, P = 0.98; no sig-
nificant contrasts). A simple one-way ANOVA indicated
no such differences at the end of the experiment either
(one-way ANOVA at t = 112 days, F(6,5) = 3.28, P = 0.1).
However, the orthogonal contrasts analysis indicated a
significant difference in the density of the control strain
versus all other colicinogenic strains (t(5) = 3.63, P =
0.015).
The doubling time of colicin producers isolated from the 
mouse GI tract
An average strain growth rate was determined from five
colonies isolated from each colicin treatment at days 0
and 112 (Table 1). An increase in growth rate was
observed for all strains, ranging from 6–33% relative to
day 0 (two-way ANOVA, F(1,48) = 84.42, P < 0.001). How-
ever, the degree of increase varied among strains, as indi-
cated by a significant interaction term (time × strain, two-
way ANOVA, F(6,48) = 3.26, P = 0.006), with the non-col-
icin producing strain experiencing the greatest increase in
growth rate (Table 1).
Discussion
The abundance and diversity of bacteriocin production in
microbial populations point to the fundamental role
these potent toxins serve in mediating strain dynamics in
microbial systems. Indeed, most species of bacteria have
been shown to possess bacteriocins [20] and levels of pro-
duction within a species can be as high as 95%. For exam-
ple, nearly 40% of the E. coli isolated from fecal samples
of animals and humans were shown to be colicinogenic
[17,18], while greater than 95% of the Pseudomonas aeru-
ginosa isolated from environmental and clinical sources
are bacteriocin producers [22].
Numerous in silico and in vitro studies have shown that
colicinogenic E. coli rapidly out-compete their colicin sen-
sitive counterparts, due to the lethality of colicin produc-
tion [9,23,10]. In the present study, the average increase
in the generation time of producer strains was lower then
that monitored for the colicin free cells (Table 1). Similar
to other E. coli strains established in streptomycin-treated
mice [24], we observed an increase of ~30% in doubling
time, while the colicinogenic strains increase in genera-
tion time was more moderate (~12% in average). In con-
trast, in an in vivo study of bacteriocins employing the
same mouse model as described here, did not detect an
increased persistence of colicinogenic enteric bacteria
[24]. However, in that study persistence was monitored
for only 15 days. Our data suggest that over a longer
period of time, 112 days in the present study, the benefit
of colicinogenicity becomes more apparent (Figure 1),
with colicin producers maintaining significantly higher
densities than their non-colicin producing counterparts.
The colicin-based advantage observed in the present in
vivo study reflects a similar advantage to colicin produc-
tion as has been detected in prior in silico and in vitro stud-
Table 1: Growth rate of E. coli strains over time
Mode of Action E. coli strains Growth rate μ1
0 days 112 days
Pore formation BZB1011 pColA-CA31 (ColA) 0.56 ± 0.03 0.51 ± 0.02
BZB1011 pColE1-K53 (ColE1) 0.54 ± 0.03 0.51 ± 0.04
BZB1011 pColK-K235 (ColK) 0.54 ± 0.03 0.47 ± 0.05
BZB1011 pColN-284 (ColN) 0.57 ± 0.02 0.48 ± 0.02
DNA degradation BZB1011 pColE2-P9 (ColE2) 0.57 ± 0.01 0.45 ± 0.04
BZB1011 pColE7-K317 (ColE7) 0.53 ± 0.02 0.42 ± 0.05
BZB1011 (S) 0.61 ± 0.03 0.41 ± 0.07
1Growth rate is expressed in generations/h.BMC Microbiology 2009, 9:165 http://www.biomedcentral.com/1471-2180/9/165
Page 5 of 7
(page number not for citation purposes)
ies [20]. Our results are even more promising with respect
to the advantage gained from colicin production when the
sampling method employed here is considered, as fecal-
based sampling will generally underestimate the actual
density of the strain in the GI tract [25,26].
There is one further colicin-based in vitro study, which
employed the same mouse model described here, but
which differed significantly in experimental design. In this
latter study the focus was on the interaction (or competi-
tion) between colicinogenic and non-colicinogenic
strains, while the current study focuses on the ability of
colicinogenicity to enhance strain maintenance [12]. This
prior colicin competition study revealed that colicin pro-
duction enhances strain persistence when mice equili-
brated with colicin producing strains are co-caged with
mice equilibrated with colicin sensitive strains [12]. Thus,
although the intent of the two studies is quite different,
both reveal that colicinogenicity has a significant and pos-
itive effect on the ability of a strain to be maintained in the
GI tract of a streptomycin-treated mouse. Many studies in
humans and livestock have shown that probiotic bacteria
have the ability to re-establish an indigenous microflora
after perturbations of the normal intestinal flora [27-31].
Probiotic bacteria provide this health benefit in many
ways and the production of toxins, in particular bacterioc-
ins, was proposed as a leading candidate in this process
[21]. E. coli strain Nissle 1917, a producer of microcins
H47 and M [32], is a well characterized probiont in
humans and livestock [3,5,33,8]. This strain was found to
be effective in treating chronic inflammatory bowel dis-
ease [33] and in inhibiting the adhesion of enteric patho-
gens to the GI epithelial cells of infants [5]. E. coli strain
H22 inhibits the invasion of the enetric pathogen Shigella
flexneri in germ-free mice, probably due to the production
of microcin C7 [34], colicins E1 and Ib, as well as aerobin
and an unidentified phage [4]. In order for a probiotic
strain to exert its beneficial effect in the GI tract, it is essen-
tial for the cells to become established. Feeding trials with
a variety of probiotic strains have shown that the strains
often disappear from the GI tract within weeks of admin-
istration [25,35]. Several studies have examined methods
to increase strain persistence using prebiotics [36]; synbi-
otic dietary supplements [26]; and addition of uptake sys-
tems. This latter mechanism involves inserting the listerial
betaine uptake system, BetL [37], into the probiotic
strains such as Bifidobacterium breve strain UCC2003 [38]
and  Lactobacillus salivarius strain UCC118 [39]. The
present study suggests that production of a bacteriocin
may serve a similar beneficial function.
Conclusion
We have shown that bacteriocin-producing strains of E.
coli, but not their bacteriocin-free counterparts, were
recovered from the feces of mice over extended periods of
sampling following a single administration of the strains.
These results suggest that colicinogenicity is beneficial in
increasing E. coli persistence in the mouse GI tract.
Methods
Bacterial strains
Six bacteriocin-encoding plasmids were chosen for this
study because they encode two of the most common kill-
ing mechanisms, pore formation and nucleic acid degra-
dation [40], known in enteric produced bacteriocins.
Moreover, the selected bacteriocins bind to their targets
via a range of cell-surface receptors (e.g., BtuB, OmpF and
Tsx) and use various translocation systems (e.g., TolA and
B) [19]. Finally, theses bacteriocins are all encoded on
small, non conjugative plasmids implying similar cost of
carriage to the host [19].
A streptomycin-resistant mutant of E. coli strain BZB1011
[12] was chemically transformed [41]. Briefly, cells were
grown in Luria Broth (LB; Sigma, St. Louis, MO) over-
night, seeded in fresh medium to grow to OD600 0.3–0.4.
The cells were then washed twice with ice-cold 100 mM of
CaCl2 (Sigma, St. Louis, MO) and diluted to yield 107-108
cells in 100 μl aliquots. A total of 2 ng of the bacteriocin's
plasmid DNA were added to each aliquot, mixed gently,
and placed on ice for 30 min. The tubes were transferred
to a water bath at 42°C for exactly 90 s and transferred
back to an ice bath for 1–2 min. A total of 100 μl of 10×
LB medium were added to each tube and incubated in a
37°C water bath for 60 min. Transformants were spread
on LB plates previously coated with the corresponding
bacteriocin lysate. The emerging colonies were isolated
and their phenotype examined as described below (see
phenotypic determination section).
Each of the resulting strains (the six colicin plasmid-bear-
ing strains as well as the colicin-free, isogenic control
strain) was established in two pairs of co-caged mice.
Fourteen cages (two per strain) were established and the
co-caged mice were permitted to interact freely. Cell den-
sity and killing phenotypes of the resident E. coli strain in
each mouse were monitored by fecal pellet plating (see
below).
Growth conditions
Luria broth (LB) and agar (Difco, Lawrence KS), and Mac-
Conkey agar (Sigma, St. Louis, MO) were prepared
according to manufacturer's instructions. M9 minimal
medium was prepared as previously described [41]. Cul-
tures were grown at 37°C with shaking at 200 rpm. Mouse
innocula were prepared from LB overnight cultures started
from a single colony on LB agar plates. The cultures were
pelleted, washed and resuspended in phosphate buffered
saline (Sigma, St. Louis, MO) to a final concentration of
109 bacteria ml-1.BMC Microbiology 2009, 9:165 http://www.biomedcentral.com/1471-2180/9/165
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Growth kinetics
Growth kinetics were measured in minimal media (M9)
with strains isolated at the beginning (day 0) and end
(day 112) of the experiment. Generation time was deter-
mined for the inoculated strain (day 0) and for five single
colonies isolated from the caged mice (one or two isolates
per mouse) at day 112. Overnight cultures grown in M9
media were diluted and grown to early exponential phase
(A600 ≈ 0.2) and culture aliquots (25 μl) were inoculated
into the wells of sterile, transparent, 96-well microtiter
plates. The plates were incubated in an Infinite M200
(Tecan, Grödig, Austria) microplate reader at 37°C with
orbital shaking. The optical density was monitored every
20 min at 600 nm wavelength and the generation time of
each colony was calculated. Growth kinetics for each
strain was measured in triplicate during each of three rep-
licate growth assays.
Mice inoculation and sampling
The mouse study was performed in compliance with fed-
eral guidelines for the ethical treatment of animals with
oversight by the Institutional Animal Care and Use Com-
mittee. Animals were kept in a conventional animal col-
ony and all experiments were approved by the animal
ethics committee of Yale University. A total of 28 mice
were treated with streptomycin to eradicate their entero-
bacterial flora and were then inoculated with the strepto-
mycin resistant BZB1011 control strain or one of the six
colicinogenic strains (four mice per treatment) and the
strains persistence was monitored for 112 days.
Twenty-eight four week-old female CD-1 mice were
obtained from Charles River Laboratories (Wilmington,
MA). Prior to bacterial inoculation and throughout the
experiment, the mice were given 5 g l-1 streptomycin sul-
fate (Sigma, St. Louis, MO) in their drinking water to elim-
inate any resident Gram-negative facultative bacteria.
After one week of preliminary streptomycin treatment, the
mice were screened for fecal enteric bacteria by plating
fecal pellets on MacConkey agar plates. All mice were free
of detectable enteric bacteria. Overnight cultures of the E.
coli strains were harvested by centrifugation, washed with
PBS, and resuspended in a one-tenth volume of PBS. Col-
onization of the E. coli strains was established by a single
administration whereby each animal received 100 μl of
~109 cells per-os. Fecal samples were taken by transferring
the mice to sterile plastic boxes, and collecting their pel-
lets as soon as they were extracted. The pellets were imme-
diately transferred to sterile, pre-weighed tubes containing
phosphate buffered saline supplemented with 25% glyc-
erol, weighed and the pellets net weight was calculated.
The samples were homogenized and sub-samples were
diluted in phosphate buffered saline for plating on selec-
tive media (MacConkey agar) supplemented with 100 μg
ml-1 streptomycin sulfate. The lower limit of detection in
fecal plate counts was 102 CFU (g feces)-1 for 100 μl of the
diluted solution per plate. The remaining samples were
stored at -80°C. Colony forming units (CFUs) were mon-
itored per gram feces.
Phenotypic determination
Crude colicin lysates were prepared according to the pro-
cedure of Suit et al [42] and stored at 4°C until use.
Twenty colonies of streptomycin-resistant E. coli from
fecal pellets obtained from each mouse at four-week inter-
vals were assayed for the production of growth inhibition
zones on plates pre-inoculated with a sensitive lawn (E.
coli strain BZB1011). Confirmation of the identity of the
colicin produced was provided by a strain's ability to grow
in the presence of its own colicins (100 μl of crude colicin
lysate spread onto LB plates), due to the immunity protein
it produces. The zones of inhibition of each strain were
documented using an imaging and documentation sys-
tem (Bio-Rad, Hercules, CA).
Statistical analysis
Each cage was treated as an independent sample and an
average of the two co-caged mice was determined. The
average number of CFUs per cage was compared at two
times, 0 and 112 days, using a one-way ANOVA. In addi-
tion, for each of these times we employed two orthogonal
contrasts to test for differences in CFUs among groups of
strains that were chosen a priori. One contrast served to
compare the average number of CFUs of the colicin-free
strain with that of the other (colicinogenic) strains. The
second served to compare the average number of CFUs of
the colicinogenic strains. A repeated-measure ANOVA was
conducted to test for differences in the persistence of the
various strains over time treating strain as a between-sub-
ject factor and time as a within-subject factor. The effects
of strain type and time (i.e. beginning vs. end of the exper-
iment) on strain doubling time were tested with a two-
way ANOVA with both strain and time treated as fixed fac-
tors. All statistical analyses were done with the STATIS-
TICA 2007 (StatSoft, Tulsa, OK).
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